Plasma stability of two glycosyl indolocarbazole antitumor agents

Biochemical Pharmacology

Volumn 65, Issue 1, 2003, Pages 25-34

  Goossens, Jean François ^a   Kluza, J érôme ^b   Vezin, Hervé ^c   Kouach, Mustapha ^a   Briand, Gilbert ^a   Baldeyrou, Brigitte ^b   Wattez, Nicole ^b   Bailly, Christian ^b  

^a UNIV LILLE   (France)

^b INSERM   (France)

^c CNRS   (France)

Author keywords

Antitumor drug; Carbohydrate; Indolocarbazole; Plasma stability; Rebeccamycin

Indexed keywords

ANTINEOPLASTIC AGENT; AT 2433 B1; BE 13793 C; CARBAZOLE DERIVATIVE; DNA TOPOISOMERASE; DRUG METABOLITE; EDOTECARIN; IMIDE; REBECCAMYCIN; UNCLASSIFIED DRUG; WATER;

ABSORPTION SPECTROSCOPY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG CONFORMATION; DRUG CYTOTOXICITY; DRUG HALF LIFE; DRUG STABILITY; DRUG STRUCTURE; ENZYME INHIBITION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYDROPHILICITY; MASS SPECTROMETRY; MOLECULAR MODEL; MOLECULAR STABILITY; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; STRUCTURE ACTIVITY RELATION; ULTRAFILTRATION;

AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; ANTINEOPLASTIC AGENTS; CARBAZOLES; DRUG STABILITY; GLUCOSIDES; HUMANS; INDOLES; MAGNETIC RESONANCE SPECTROSCOPY; MASS SPECTROMETRY; MODELS, MOLECULAR; PLASMA; WATER;

EID: 0037212621     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(02)01418-1     Document Type: Article

References (27)

1. Bailly C. Topoisomerase I poisons and suppressors as anticancer drugs. Current Med. Chem. 7:2000;39-58.
2. Long B.H., Balasubramanian B.N. Non-camptothecin topoisomerase I compounds as potential anticancer agents. Exp. Opin. Ther. Patents. 10:2000;635-666.
3. Yoshinari T., Matsumoto M., Arakawa H., Okada H., Noguchi K., Suda H., Okura A., Nishimura S. Novel antitumor indolocarbazole compound 6-N-formylamino-12,13-dihydro-1,11-dihydroxy-13-(β-D-glucopyranosyl)- 5H-indolo[2,3-a]pyrrolo-[3,4-c]carbazole-5,7-(6H)-dione (NB-506): induction of topoisomerase I-mediated DNA cleavage and mechanisms of cell line-selective cytotoxicity. Cancer Res. 55:1995;1310-1315.
4. Arakawa H., Matsumoto H., Morita M., Sasaki M., Taguchi K., Okura A., Nishimura S. Antimetastatic effect of a novel indolocarbazole (NB-506) on IMC-HM murine tumor cells metastasized to the liver. Jpn. J. Cancer Res. 87:1996;518-523.
5. Arakawa H., Iguchi T., Morita M., Yoshinari T., Kojiri K., Suda H., Okura A., Nishimura S. Novel indolocarbazole compound 6-N-formylamino-12,13-dihydro-1,11-dihydroxy-13-(β-D-glucopyranosyl)- 5H-indolo[2,3-a]pyrrolo-[3,4-c]carbazole-5,7-(6H)-dione (NB-506): its potent antitumor activities in mice. Cancer Res. 55:1995;1316-1320.
6. Kanzawa F., Nishio K., Kubota N., Saijo N. Antitumor activities of a new indolocarbazole substance, NB-506, and establishment of NB-506-resistant cell lines, SBC-3/NB. Cancer Res. 55:1995;2806-2813.
7. Vanhoefer U., Voigt W., Hilger R.A., Yin M.B., Harstrick A., Seeber S., Rustum Y.M. Cellular determinants of resistance to indolocarbazole analogue NB-506. A novel potent topoisomerase I inhibitor, in multidrug-resistant human tumor cells. Oncol. Res. 9:1997;485-494.
8. Sasaki Y., Tanigawara Y., Fujii H., Ohtsu T., Wakita H., Igarashi T., Itoh K., Ogino H., Takenaga N., Okada K., Nishimura S., Abe K. Phase I and pharmacology study of NB-506. Proc. Am. Soc. Clin. Oncol. 14:1995;172.
9. Ohe Y., Tanigawara Y., Fujii H., Ohtsu T., Wakita H., Igarashi T., Minami H., Eguchi K., Shinkai T., Tamura T., Kunotoh H., Saijo N., Okada K., Ogino H., Sasaki Y. Phase I and pharmacology study of 5-day infusion of NB-506. Proc. Am. Soc. Clin. Oncol. 16:1997;199a.
10. Bailly C. Targeting DNA and topoisomerase I with indolocarbazole antitumor agents. In: Demeunynck M, Bailly C, Wilson WD, editors. DNA and RNA Binders, From Small Molecules to Drugs. Wiley; 2002, in press.
11. Ohkubo M., Kojiri K., Kondo H., Tanaka S., Kawamoto H., Nishimura T., Nishimura I., Yoshinari T., Arakawa H., Suda H., Morishima H., Nishimura S. Synthesis and biological activities of topoisomerase I inhibitors, 6-N-amino analogues of NB-506. Bioorg. Med. Chem. Lett. 9:1999;1219-1224.
12. Yoshinari T., Ohkubo M., Fukasawa K., Egashira S., Hara Y., Matsumoto M., Nakai K., Arakawa H., Morishima H., Nishimura S. Mode of action of a new indolocarbazole anticancer agent, J-107088, targeting topoisomerase I. Cancer Res. 59:1999;4271-4275.
13. Arakawa H., Morita M., Kodera T., Okura A., Ohkubo M., Morishima H., Nishimura S. In vivo antitumor activity of a novel indolocarbazole compound, J-107088, on murine and human tumors transplanted into mice. Jpn. J. Cancer Res. 90:1999;1163-1170.
14. Cavazos C.M., Keir S.T., Yoshinari T., Bigner D.D., Friedman H.S. Therapeutic activity of the topoisomerase I inhibitor J-107088 [6-N-(1-hydroxymethyla-2-hydroxyl)ethylamino-12,13-dihydro-13-(beta-D- glucopyranosyl)-5H-indolo[2,3-a]-pyrrolo[3,4-c]-carbazole-5,7(6H)-dione]] against pediatric and adult central nervous system tumor xenografts. Cancer Chemother. Pharmacol. 48:2001;250-254.
15. Bailly C., Dassonneville L., Colson P., Houssier C., Fukasawa K., Nishimura S., Yoshinari T. Intercalation into DNA is not required for inhibition of topoisomerase I by indolocarbazole antitumor agents. Cancer Res. 59:1999;2853-2860.
16. Bailly C., Qu X., Chaires J.B., Colson P., Houssier C., Ohkubo M., Nishimura S., Yoshinari T. Substitution at the F-ring N-imide of the indolocarbazole antitumor drug NB-506 increases the cytotoxicity, DNA binding and topoisomerase I inhibition activities. J. Med. Chem. 42:1999;2927-2935.
17. Takenaga N., Ishii M., Nakajima S., Hasegawa T., Iwasa R., Ishizaki H., Kamei T. In vivo metabolism of a new anticancer agent, 6-N-formylamino-12,13-dihydro-1,11-dihydroxy-13-(β-D-glucopyranosil)- 5H-indolo [2,3-a]pyrrolo [3,4-c]carbazole-5,7(6H)-dione (NB-506) in rats and dogs: pharmacokinetics, isolation, identification, and quantification of metabolites. Drug Metab. Dispos. 27:1999;205-212.
18. Takenaga N., Hasegawa T., Ishii M., Ishizaki H., Hata S., Kamei T. In vitro metabolism of a new anticancer agent, 6-N-formylamino-12,13-dihydro-1,11-dihydroxy-13-(β-D-glucopyranosil)- 5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7(6H)-dione (NB-506), in mice, rats, dogs, and humans. Drug Metab. Dispos. 27:1999;213-220.
19. Ohkubo M., Kawamoto H., Ohno T., Nakano M., Morishima H. Synthesis of NB-506, a new anticancer agent. Tetrahedron. 53:1997;585-592.
20. Halgren T.A. Merk Molecular Force Field. III. Molecular geometries and vibrational frequencies for MMFF94. J. Comput. Chem. 17:1996;553-586.
21. Halgren T.A., Nachbar R.B. Merk Molecular Force Field. IV. Conformational energies and geometries for MMFF94. J. Comput. Chem. 17:1996;587-615.
22. Pilch B., Allemand E., Facompré M., Bailly C., Riou J.F., Soret J., Tazi J. Specific inhibition of SR splicing factors phosphorylation, spliceosome assembly and splicing by the antitumor drug NB506. Cancer Res. 61:2001;6876-6884.
23. Urasaki Y., Laco G., Takebayashi Y., Bailly C., Kohlhagen G., Pommier Y. Use of camptothecin-resistant mammalian cell lines to evaluate the role of topoisomerase I in the antiproliferative activity of the indolocarbazole, NB-506, and its toposiomerase I binding site. Cancer Res. 61:2001;504-508.
24. Bailly C., Carrasco C., Hamy F., Vezin H., Prudhomme M., Saleem A., Rubin E. The camptothecin-resistant topoisomerase I mutant F361S is cross-resistant to antitumor rebeccamycin derivatives. A model for topoisomerase I inhibition by indolocarbazoles. Biochemistry. 38:1999;8605-8611.
25. Anizon F., Belin L., Moreau P., Sancelme M., Voldoire A., Prudhomme M., Ollier M., Sevère D., Riou J.F., Bailly C., Fabbro D., Meyer T. Syntheses and biological activity (topoisomerases inhibition, antitumoral and antimicrobial properties) of rebeccamycin analogues bearing modified sugar moieties and substituted on the imide nitrogen with a methyl group. J. Med. Chem. 40:1997;3456-3465.
26. Moreau P., Anizon F., Sancelme M., Prudhomme M., Bailly C., Ollier M., Sevère D., Riou J.F., Fabbro D., Meyer T., Aubertin A.M. Syntheses and biological activities of rebeccamycin analogues. Introduction of a halogenoacetyl substituent. J. Med. Chem. 42:1999;584-592.
27. Moreau P., Anizon F., Sancelme M., Prudhomme M., Bailly C., Carrasco C., Ollier M., Sevère D., Riou J.F., Fabbro D., Meyer T., Aubertin A.M. Syntheses and biological evaluation of indolocarbazoles, analogues of rebeccamycin, modified at the imide heterocycle. J. Med. Chem. 41:1998;1631-1640.